Search

Displaying results 3931 - 3940 of 9333 in total
  1. Drug

    Benazeprilat

    go.drugbank.com/drugs/DB14125
    Experimental

    Categories: Agents Acting on the Renin-Angiotensin System
  2. Drug

    Ibritumomab tiuxetan

    go.drugbank.com/drugs/DB00078
    Approved

    Indium or yttrium conjugated murine IgG1 kappa monoclonal antibody directed against the CD20 antigen, which is found on the surface of normal and malignant B lymphocytes.

  3. Drug

    Ridogrel

    go.drugbank.com/drugs/DB01207
    Experimental

    Ridogrel is a dual action drug useful for the prevention of systemic thrombo-embolism and as an adjunctive agent to thrombolytic therapy in acute myocardial infarction.

  4. Drug

    NOX-100

    go.drugbank.com/drugs/DB05799
    Investigational

    NOX-100 is the first in a series of proprietary NO neutralizing compounds Medinox is developing to bind and inactivate NO, a simple gas molecule that is a key biological messenger in the body. … NOX-100 is the new nitric oxide (NO) neutralizing agent being developed by San Diego-based Medinox -- demonstrated its effectiveness and potential as a therapeutic to treat hemorrhagic shock.

  5. Drug

    Butoconazole

    go.drugbank.com/drugs/DB00639
    Approved

    Butoconazole is an imidazole antifungal used in gynecology.

  6. Drug

    Flucloxacillin

    go.drugbank.com/drugs/DB00301
    ApprovedInvestigationalWithdrawn

    Antibiotic analog of cloxacillin.

  7. Drug

    DG051

    go.drugbank.com/drugs/DB05177
    Experimental

    DG051 is a novel small-molecule inhibitor of leukotriene A4 hydrolase (LTA4H), the protein made by one of the genes in the leukotriene pathway that has been shown to link to risk of heart attack. … DG051 is designed to decrease risk of heart attack by decreasing the production of leukotriene B4 (LTB4), an end product of the leukotriene pathway and a potent promoter of inflammation.

  8. Drug

    Cocamidopropyl betaine

    go.drugbank.com/drugs/DB11350
    Approved

    Impurities formed during the manufacturing process are thought to increase the prevalence of contact sensitization and mild skin irritations.

  9. Drug

    SP1049C

    go.drugbank.com/drugs/DB04978
    Experimental

    Preliminary data, in its first clinically tested indication, shows that SP1049C is active in Stage IV non-resectable adenocarcinoma of the esophagus. … [A260416] It is designed to overcome drug resistance in a number of cancers. It has successfully completed Phase 1 trials. Phase 2 results are currently under final review.

  10. Drug

    Oxilofrine

    go.drugbank.com/drugs/DB11610
    Approved

    It is currently marketed in Canada by Valeant under the tradename Cophylac.